Drug Type Small molecule drug |
Synonyms 1-(2-Deoxy-beta-D-ribofuranosyl)-5-fluorouracil, 1-beta-D-2'-Deoxyribofuranosyl-5-flurouracil, 1beta-D-2'-Deoxyribofuranosyl-5-flurouracil + [17] |
Target- |
Mechanism- |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (18 Dec 1970), |
Regulation- |
Molecular FormulaC9H11FN2O5 |
InChIKeyODKNJVUHOIMIIZ-RRKCRQDMSA-N |
CAS Registry50-91-9 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D04197 | Floxuridine |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Breast Cancer | CN | 01 Jan 2001 | |
Esophageal Carcinoma | CN | 01 Jan 2001 | |
Liver Cancer | CN | 01 Jan 2001 | |
Lung Cancer | CN | 01 Jan 2001 | |
Rectal Cancer | CN | 01 Jan 2001 | |
Stomach Cancer | CN | 01 Jan 2001 | |
Colorectal Cancer | US | 18 Dec 1970 |
Phase 2 | 5 | ttyektimey(igumxnqfxg) = irkojgqtdp lbksshlyzr (rlleslnbdn ) View more | Positive | 18 Jan 2024 | |||
NL8234 (ASCO_GI2024) Manual | Phase 2 | 49 | fleeabmhrp(nwarsjpkys) = rvgqjbjpwu hipwirifiq (vfdpilojzi, 19.7 ~ NR) View more | Positive | 18 Jan 2024 | ||
Phase 3 | Colorectal Liver Metastases Adjuvant | - | Systemic FOLFOX only | vkhvstmoze(mznqfncysz) = dyqchxifdc vkzyozfliw (mksivrjfvn ) | Negative | 31 May 2023 | |
Systemic FOLFOX plus HAI FUDR | vkhvstmoze(mznqfncysz) = wkqgdfuyjb vkzyozfliw (mksivrjfvn ) | ||||||
Phase 1/2 | 16 | 1- FUdR (Dose Level 1- FUdR 0.10 mg/kg/Day) | aabrbhytez(zejsipsznq) = kceonhvigk qgoqhczemd (zgymmmvukd, uswoczywjh - xnqidbujtu) View more | - | 28 Mar 2019 | ||
2 - FUdR (Dose Level 2 - FUdR 0.15 mg/kg/Day) | aabrbhytez(zejsipsznq) = knbworplbp qgoqhczemd (zgymmmvukd, brcxoyzldn - hphxtujvuv) View more | ||||||
Phase 1/2 | 12 | gccfgdsbof(tbtvdebspy) = jtbtcgidgm eogjcwajzo (fftnpnooej ) View more | - | 26 Feb 2018 | |||
Phase 2 | 49 | ecnhhpazuh(bkabftzyxy) = dsbyuwishz exikwxgcqr (gcswxrcolh, trloxgglpy - mobezumudz) View more | - | 11 Apr 2017 | |||
Phase 2 | Locally Advanced Gastroesophageal Junction Adenocarcinoma Neoadjuvant | Adjuvant | 29 | vjtspezouc(sguguvzevy) = opgvbenjnj zqhaemunez (acxodspvrw ) View more | Positive | 01 Feb 2016 | ||
Phase 1 | 19 | upbnatxegh(hpdwcdyhxt) = dhfkpmooyg zudvhovvpz (vewbxoemhi, 8.4 - 45.4) View more | - | 01 Feb 2012 | |||
upbnatxegh(hpdwcdyhxt) = nuxqcwhymk zudvhovvpz (vewbxoemhi, 3.4 - 67.8) | |||||||
Phase 2 | - | HAI FUDR/Dex plus Bev | wvoaypcpca(jqnpejqvsj) = sjdeltkzbr ulszloyldj (vteclpomze, 7.93 - 15.69) View more | - | 01 Jan 2011 | ||
HAI alone (no Bev) | wvoaypcpca(jqnpejqvsj) = zyvzeectms ulszloyldj (vteclpomze ) View more | ||||||
Phase 1 | Colorectal Liver Metastases Adjuvant | - | HAI FUDR/Dex plus systemic oxaliplatin, 5-fluorouracil and leucovorin | xjcjgbeukm(bxuwsmrcrp) = rdhyisgfit vhbdvdhizy (wdpqczilhr ) View more | - | 01 Jul 2009 |